The Covenant
By Peter J. Boyer,
The New Yorker
| 09. 06. 2010
When the geneticist Francis Collins was named director of the National Institutes of Health, last summer, he became the public face of American science and the keeper of the world’s deepest biomedical-research-funding purse. He was praised by President Obama and waved through the Senate confirmation process without objection. There also came a peer review of a sort that he’d never experienced, conducted in the press and in Internet science forums. Collins read in the Times that many of his colleagues in the scientific community believed that he suffered from “dementia.” Steven Pinker, a cognitive psychologist at Harvard, questioned the appointment on the ground that Collins was “an advocate of profoundly anti-scientific beliefs.” P. Z. Myers, a biologist at the University of Minnesota at Morris, complained, “I don’t want American science to be represented by a clown.”
Collins’s detractors did not question his professional achievements, which long ago secured his place in the first rank of international scientists. As a young researcher at Yale, Collins conceived a method of hastening the laborious process of hunting disease-causing genes by skipping across long...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...